Stocks and Investing
Stocks and Investing
Thu, March 22, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, March 21, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, March 20, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Alethia Young Maintained (ASND) at Buy with Increased Target to $78 on, Mar 20th, 2018
Alethia Young of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $50 to $78 on, Mar 20th, 2018.
Alethia has made no other calls on ASND in the last 4 months.
There is 1 other peer that has a rating on ASND. Out of the 1 peers that are also analyzing ASND, 0 agree with Alethia's Rating of Hold.
This is the rating of the analyst that currently disagrees with Alethia
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $60 on, Thursday, January 25th, 2018
Contributing Sources